Targeting oncogene promoters: a novel heterocyclic cations as G-quadruplex stabilizing ligands Lenka Pohlová Abstract: The diploma thesis studies an effect of newly synthesized group of compounds - helquats - on the expression of c-myc as a major player in malignant transformation and tumorigenesis via the stabilization of G-quadruplex in c-myc promotor. The G-quadruplex c-myc stabilization ability was tested for 101 helquats using dual luciferase reporter assay. The G-quadruplex c-myc stabilization ability was found for 13 helquats by this method. 8 successful helquats was selected by a comparison of the results from dual luciferase reporter assay and FRET melting assay. Effect on cell viability of tumor (HeLa S3) and non-tumor (HUVEC) cell lines was evaluated for these 8 helquats. Three of them exhibited cytotoxic effect on tumor cells but no effect was observed on viability of non-tumor cells. Moreover, an effect of these 3 helquats on c-myc expression on both mRNA and protein level, where significant effect on c-myc mRNA expression was not found for most of incubation periods. The 30% decrease in mRNA level was observed only for 24 hours incubation period for two helquats (LS702 and MJ656). The decrease in the expression on protein level was observed for all tested helquats, and helquat LS702 had the...

Watson-Crick paired B-form DNA is the genetic material in most of the biological systems. Integrity of DNA is of utmost importance for the normal functioning of any organism. Various environmental factors, chemicals and endogenous agents constantly challenge integrity of the genome resulting in mutagenesis. Over the past few decades multiple reports suggest that DNA can adopt alternative conformations other than the right handed double helix. Such structures occur within the context of B-DNA as sequence dependent structural variations and are facilitated by free energy derived from negative supercoiling, which may be generated during physiological processes like transcription, replication, etc. or binding of proteins. Multiple groups have shown that these structures render fragility to the genome owing to single-strandedness (presence of unpaired bases). This conformational polymorphism of the DNA is due to the presence of several repetitive elements across the genome. Some of the common non-B DNA structures include Z-DNA, H-DNA (triplex DNA), cruciform DNA, G-quadruplexes and RNA: DNA hybrid (R-loops). Over the past few decades G-quadruplex structures have gained tremendous importance owing to its role in physiology and pathology. Recently it has been shown that novel sequence motifs, called GNG or bulges can fold into G-quadruplexes, thus increasing the propensity of such structures genome-wide. Neurological diseases, psychiatric diseases and genomic disorders (due to deletions, translocations, duplications and inversions) are some of the consequences of non-B DNA structures in the human genome. Inadvertent genomic rearrangements in human can lead to different diseases including cancer. Immediate consequence of genomic rearrangement includes structural alteration of genome through joining of distant sequences. t(8;14) translocation is the hallmark of Burkitt’s lymphoma, which results in deregulation of c-MYC gene that may contribute to oncogenic transformation. In the present study, we delineate the causes of fragility within the c-MYC gene. In order to do this, breakpoints at the c-MYC locus from Burkitt’s lymphoma patient sequences reported in database were plotted and analysed. Interestingly, unlike many other translocations, breakpoints at c-MYC locus were widespread, except for a cluster of breakpoints downstream to promoter 2 (P2). Previous studies indicate that the translocation breakpoint clusters often correlate with formation of non-B DNA structures. The entire breakpoint cluster downstream of P2 was divided into Region 1, Region 2 and Region 3. Interestingly, in silico analysis of the breakpoint clusters revealed no evidence for predictive classic non-B DNA motifs in Region 2; whereas Region 1 harboured a G-quadruplex motif on the template strand and Region 3 had two short inverted repeats. Intriguingly, as the nontemplate strand of Region 2 was G skewed with a good number of AID binding motifs, we tested the MYC breakpoint Region 2 for its potential to form R-loop due to binding of nascent RNA to template DNA. Our results showed that MYC Region 2 can form RNA-DNA hybrid in a transcription dependent manner in physiological orientation. Observed structure was sensitive to RNase H. We showed Region 2 hindered action of Dpn I upon transcription confirming formation of R-loop structure. Owing to single strandedness, Region 2 R-loop was shown to be sensitive to P1 nuclease as opposed to the untranscribed control. The single strandedness of the Region 2 R-loop was characterized at a single molecule level through bisulfite modification assay. The assay corroborated formation of R-loop along with providing snapshots of various length R-loops formed upon Region 2 transcription. Besides, various biophysical and biochemical assays showed the complementary region (template strand) to be single-stranded in stretches, upon transcription. Length of RNA within the R-loop was within a range of 75 to 250 nt. To delineate the mechanism of R-loop formation we tested the sensitivity of R-loop formation to RNase A during and post transcription; and found that R-loop formation was abrogated in presence of RNase A during transcription suggesting that R-loop formation followed a “thread back model”. Intriguingly we observed that two short regions of the template strand exhibited high degree of single strandedness. To investigate the reason for such unusual single strandedness, oligonucleotides spanning the region was designed and subjected for CD and EMSA studies. EMSA showed robust intramolecular G-quadruplex structure formation in presence of KCl, whereas CD confirmed that both regions formed parallel G-quadruplexes. We also showed the precise involvement of guanines in structure formation through DMS protection assay. Further, the region of interest was cloned into appropriate vectors and primer extension assays were performed in presence of G-quadruplex stabilizing agents like TMPyP4 and KCl. Increasing concentration of these stabilizing agents enhanced the formation of G-quadruplexes in a double stranded context, which hindered polymerase progression. Since these G-quadruplex structures utilized sequences which are deviant to the consensus of G-quadruplex motifs, non-B DNA predicting tools were unable to score them. On closer analysis of the sequences we found that, these G-quadruplexes involve duplex hairpin and GNG motifs during structure formation. Besides, both the G-quadruplexes were highly thermostable and were able to fold back upon renaturation. Till recently, it has been believed that G-quadruplex structures are formed using a minimum of four, 3 guanine tracts, with connecting loops ranging from one to seven. Recent studies have reported deviation from this general convention. One such deviation is the involvement of bulges in the guanine tracts. In the present study, guanines along with GNG motifs have been extensively studied using recently reported HOX11 breakpoint fragile region I as a model template. By strategic mutagenesis approach we show that the core elements of a G-quadruplex are not equally important in structure formation when flanked by GNG motifs. Importantly, the positioning and number of GNG/GNGNG can dictate the formation of G-quadruplexes. In addition to HOX11 fragile region, GNG motifs of HIF1-alpha can fold into intramolecular G-quartet. However, GNG motifs in mutant VEGF sequence could not participate in structure formation, suggesting that the usage of GNG is context dependent. Importantly, we show that when two stretches of guanines are flanked by two independent GNG motifs in a naturally occurring sequence (SHOX), it can fold into an intramolecular G-quadruplex. Interestingly, intra molecular GNG G-quadruplexes were able to fold back after complete denaturation of the oligonucleotides. Besides one of the intra molecular GNG G-quadruplexes was purified and confirmed for parallel conformation. Finally, we show the specific binding of G-quadruplex binding protein, Nucleolin and G-quadruplex antibody BG4 to SHOX G-quadruplex through EMSA studies. Thus, the study provides novel insights into the role of GNG motifs in G-quadruplex structure formation, which may have both physiological and pathological implications. In conclusion, we show formation of transcription dependent R-loop and G-quadruplex structures at the c-MYC gene locus in a mutually exclusive manner. The data presented here, in conjunction with studies from other laboratories suggests that these structures could impart fragility within the c-MYC gene locus during t(8;14) translocation. Besides, we characterised unusual G-quadruplexes harbouring GNG motifs. We find that positioning and number of GNG can dictate the formation of G-quadruplexes and is context dependent.

Many polypeptide growth factors act by binding to cell surface receptors that have intrinsic tyrosine kinase activity. Binding of these growth factors to their cognate receptors results in the initiation of mitogenic signals which then get transduced to the interior of the cell. A critical target for extracellular signals is the nucleus. A plethora of recent evidence indicates that extracellular signals can affect nuclear gene expression by modulating transcription factor activity. In this study, I have determined that the transactivation domain of c-Myc (protein product of the c-myc proto-oncogene) is a direct target of mitogen-activated signaling pathways involving protein kinases. Further, my study demonstrates that transactivation of gene expression by c-Myc is regulated as a function of the cell cycle. c-Myc is a sequence-specific DNA binding protein that forms leucine zipper complexes and can act as a transcription factor. Although, significant progress has been made in understanding the cellular properties of c-Myc, the precise molecular mechanism of c-Myc function in oncogenesis and in normal cell growth is not known. I have focused my attention on the property of c-Myc to function as a sequence-specific transcription factor. In my studies, I have employed a fusion protein strategy, where the transactivation domain of the transcription factor c-Myc is fused to the DNA binding domain and nuclear localization signal of the yeast transcription factor GAL4. This fusion protein was expressed together with a plasmid consisting of specific GAL4 binding sites cloned upstream of a minimal E1b promoter and a reporter gene. The activity of the c-Myc transactivation domain was measured as reporter gene activity in cell extracts. This experimental approach enabled me to directly monitor the activity of the c-Myc transactivation domain. Results listed in Chapter II demonstrate that the transactivation domain of c-Myc at Ser-62 is a target of regulation by mitogen-stimulated signaling pathways. Furthermore, I have determined that a mitogen activated protein kinase, p41mapk, can phosphorylate the c-Myc transactivation domain at Ser-62. Phosphorylation at this site results in a marked increase in transactivation of gene expression. A point mutation at the MAP kinase phosphorylation site (Ser-62) causes a decrease in transactivation. c-Myc expression is altered in many types of cancer cells, strongly implicating c-myc as a critical gene in cell growth control. The molecular mechanisms by which c-Myc regulates cellular proliferation are not understood. For instance, it is not clear where in the cell cycle c-Myc functions and what regulates its activity. In exponentially growing cells, the expression levels of c-Myc remain unchanged as the cells progress through the cell cycle. The function of c-Myc may therefore be regulated by a mechanism involving a post-translational modification, such as phosphorylation. Results described in chapter IV demonstrate that the level of c-Myc mediated transactivation oscillates as cells progress through the cell cycle and was greatly increased during the S to G2/M transition. Furthermore, mutation of the phosphorylation site Ser-62 in the c-Myc transactivation domain diminishes this effect, suggesting a functional role for this phosphorylation site in the cell cycle-specific regulation of c-Myc activity. Taken together, my dissertation study reveals a molecular mechanism for the regulation of nuclear gene expression in response to mitogenic stimuli.

c-MYC est un proto-oncogène surexprimé dans les lymphomes de Burkitt et une cible importante pour le traitement de ces maladies. La protéine à domaine BTB/POZ MIZ-1 est un partenaire direct de la protéine c-MYC. En effet, c-MYC via son structure hélice-boucle-hélice se lie précisément à la séquence entre le 12e et 13e doigt de zinc de MIZ-1. Notre groupe a démontré que l’expression de la protéine MIZ-1 tronquée de son domaine POZ (MIZ-1ΔPOZ) peut ralentir la lymphomagenèse. Pourtant, l’interaction directe entre c-MYC et MIZ-1 n’est pas affectée par la délétion du domaine POZ de MIZ-1. Ceci suggère que MIZ-1 est important pour l’activité oncogénique de c-MYC. Il a été observé que l’expression de MIZ-1ΔPOZ diminue le nombre de cellules B pré-tumorales dans les modèles murins de lymphomes Eμ-Myc et Igλ-Myc. De plus, les niveaux protéiques très élevés de c-MYC dans les cellules B Eμ-Myc sont diminués lorsque MIZ-1ΔPOZ est exprimé. Toutefois, l’activité du protéasome ne semble pas être responsable de la diminution de c-MYC. Une analyse des interactions protéiques de MIZ-1 par BioID effectuée par notre groupe a montré que MIZ-1 et MIZ-1ΔPOZ interagissent avec PP1ɣ, TOX4 et PNUTS, trois protéines du complexe PTW/PP1 qui est un complexe transcriptionnel dont c-MYC fait partie. Des résultats de co-IP confirment cette interaction ce qui suggère que MIZ-1 pourrait influencer l’activité de ce complexe. De plus, une lignée cellulaire dans laquelle MIZ-1ΔPOZ est exprimé a été établie ce qui permettra d’approfondir l’étude des interactions protéiques de MIZ-1 avec le complexe PTW/PP1 et d’étudier l’effet de MIZ-1ΔPOZ sur l’activité transcriptionelle de ce complexe. Une meilleure compréhension du mécanisme d’action de MIZ-1 sur c-MYC permettra de mieux comprendre son rôle dans un contexte pathologique, ce qui pourrait permettre le design de nouvelles approches thérapeutiques. / c-MYC is a proto-oncogene overexpressed in Burkitt's lymphoma and an important target for the treatment of these diseases. The BTB/POZ domain protein MIZ-1 is direct a partner of c- MYC. Indeed, c-MYC via its helix-loop-helix structure binds precisely to the sequence between the 12th and 13th zinc finger of MIZ-1. We demonstrated that expression of MIZ-1 that lacks its POZ domain (MIZ-1ΔPOZ) can impair lymphomagenesis. However, the direct interaction between c-MYC and MIZ-1 is not affected by the deletion of the MIZ-1 POZ domain. This suggests that MIZ-1 is important for the oncogenic activity of c-MYC. We observed that expression of MIZ-1ΔPOZ decreases the number of pre-tumor B cells in lymphomas mouse models such as Eμ-Myc and Igλ-Myc. The high c-MYC protein levels observed in Eμ-Myc B cells are decreased when MIZ-1ΔPOZ is expressed. However, proteasome activity does not seem to be responsible for the decrease of c-MYC. After the analysis of MIZ-1 protein interactions by BioID, our group found that MIZ-1 and MIZ-1ΔPOZ interact with PP1ɣ, TOX4 and PNUTS, three proteins of the PTW/PP1 complex which also interact with c-MYC. Co-IP results confirmed these interactions suggesting that MIZ-1 could influence the activity of this complex. In addition, a MIZ- 1ΔPOZ cell line was established which will allow further studies of MIZ-1ΔPOZ protein interactions with the PTW/PP1 complex as well as its effect on the transcriptional activity of this complex. A better characterization of the mechanism of action of MIZ-1 on c-MYC will lead to a better understanding of its role in a pathological context, which could be the basis of new therapeutic approaches.

CD8+ T cells are critical to the adaptive immune response and are a target for vaccine development. However, the complex dynamics of cell proliferation can vary response success, providing uncertainty when designing vaccines. Computer models can provide clarity by simulating these dynamics, tracking millions of cell-cell interactions, a feat that is impractical experimentally. Our group created the STORE.1 model, a probabilistic simulation of the CD8+ T cell response to vaccination. While able to accurately simulate in vivo mouse T cell clonal expansion, intracellular dynamics are absent. Furthermore, there is no mechanism by which cell division ceases. This work builds upon the STORE.1 model by systematically explaining the division dynamics of CD8+ T cells and providing measures of the extracellular environment. The new STORE.2 model has demonstrated an ability to accurately simulate differences in CD8+ T cell expansion in WT mice and mice lacking type I conventional dendritic cells up to 170 hours after vaccination. It is the first model to simulate individual cell cycle regulator protein counts for millions of cells, and the resulting impact on pH for the extracellular microenvironment. Finally, it provides a partial mechanism behind division cessation, an important element for future models seeking to further simulate the end of the T-cell response. / Thesis / Master of Applied Science (MASc) / T-cells are an important component of the human immune system, but currently, there are no vaccines in clinical use that are designed to target them. This is because there are many different dynamics that underpin how T-cells activate, and to what degree they can replicate into a substantial pool of pathogen-clearing cells. Learning which candidate vaccines can properly elicit a strong T-cell response is time and resource consuming. Mathematical models can therefore speed development of candidate vaccines by virtually testing their T-cell responsiveness. This thesis works to improve on an existing mathematical model by introducing immunological mechanisms that determine how T-cells undergo cell division, change the acidity of their immediate surroundings, and respond to their own growing population. By doing so, this new model can be more representative of the immunological reality and begin to probe new dynamics of the T-cell response.

No description available.

Introdução: O Câncer de Próstata (CaP) é o tumor mais comum do homem e a segunda causa de óbito por câncer no Brasil. MicroRNA (miRNA) é uma classe de pequenos RNA regulatórios não codificantes de proteínas que tem papel fundamental no controle da expressão dos genes. São responsáveis pelo controle de processos fundamentais na célula e estão envolvidos na tumorigênese em humanos. Previamente demonstramos alterações no perfil de expressão dos miRNA 100, let7c e 218 comparando carcinomas localizados e metastáticos. A caracterização de perfis de expressão de suas proteínas alvo no CaP é crucial para a compreensão dos processos envolvidos na carcinogênese, dando-nos a oportunidade do descobrimento de novos marcadores diagnósticos, prognósticos e mais importante identificação de alvos para o desenvolvimento de terapias inovadoras. Objetivo: Analisar a expressão das proteínas controladas pelo miR-let7c (Ras, c-Myc e Bub1), miR-100 (Smarca5 e Retinoblastoma) e miR-218 (Laminina 5 3) e a atividade proliferativa (Ki-67) no câncer de próstata com a técnica de imuno-histoquímica utilizando microarranjos teciduais representativos de CaP localizado e suas metástases linfonodais e ósseas. Correlacionar os níveis de expressão dos miRNA com suas proteínas alvo. Analisar a expressão dos miRNA, proteínas e atividade proliferativa com os fatores prognósticos do câncer de próstata e com a evolução da doença. Material e Métodos: A imunoexpressão de Smarca5, Retinoblastoma, Laminina, Ras, c- Myc, Bub1 e Ki-67 foi avaliada através de IH pela técnica de microarranjo tecidual caracterizando três estágios do CaP, sendo 112 casos de CaP localizado, 19 metástases linfonodais e 28 metástases ósseas. As imagens obtidas foram submetidas a um software de análise de imagem digital MacBiophotonics ImageJ do National Institutes of Health, EUA, onde a intensidade de luminescência foi quantificada densitometricamente. O perfil de expressão dos miR-let7c, 100 e 218 foi analisado utilizando o bloco de parafina de 61 pacientes dos 112 pacientes com carcinoma localizado, que foram submetidos a analise protéica por IH. O processamento dos miRNA envolveu três etapas: extração do miRNA com kit específico, geração do DNA complementar e amplificação do miRNA por PCR quantitativo em tempo real (qRT-PCR) cujo controle endógeno foi RNU-43 (Applied Biosystems). Os resultados foram analisados usando o método 2-CT. Como controle, utilizamos amostras de tecido com hiperplasia prostática benigna (HPB). Avaliamos a relação entre a expressão dos miRNA e suas proteínas alvo, com o escore de Gleason, estadiamento patológico e evolução da doença considerando recidiva bioquímica, níveis de PSA>0,4 ng/mL, em uma média de seguimento de 77,5 meses. A análise estatística foi realizada através do software SPSS 19.0, utilizamos o test T de Student, Mann-Whitney, Kruskal-Wallis e qui-quadrado. O valor de p foi considerado estatisticamente significante quando inferior na 0,05 em todos os cálculos. Resultados: Observamos uma diminuição de expressão de Ras (p=0,017) e Laminina (p<0,0001) conforme a progressão tumoral do CaP localizado a metástase linfonodal e óssea. Houve um aumento de expressão de Rb (p=0,0361) e aumento da atividade proliferativa avaliada pelo Ki- 67 (p<0,0001). Encontramos ainda uma tendência a relação entre a positividade de expressão de c-Myc com estadiamento patológico pT3 (p=0,070). Todos os miRNA se mostraram superexpressos no CaP localizado. Laminina apresentou uma média de intensidade de expressão maior quanto maior a expressão de miR-218 (p=0,038). Porém os demais miRNA não apresentaram relação de expressão com suas proteínas alvo. Também não houve relação entre a expressão de miRNA e expressão das proteínas por IH com a recidiva bioquímica. Conclusões: Apesar de confirmarmos os nossos achados de superexpressão dos miRNA 100, let7c e 218 no CaP localizado, não houve correlação entre esses e a imunoexpressão de suas proteínas alvo. Demonstramos que houve alteração de imunoexpressão de Ras, Laminina 5 3, Retinoblastoma e Ki-67 de acordo com a progressão tumoral no CaP. E uma maior expressão de c-Myc por IH mostrou uma significância tendência a relacionar-se com tumores não confinados estadiados pT3 / Introduction: Prostate cancer (PCa) is the most common tumor in men and the second leading cause of cancer death in men in Brazil. MicroRNA (miRNA) is a class of small non-coding RNA that plays a key role in the control of gene expression. They are responsible for the control of key processes in the cell and are involved in tumorigenesis in humans. Previously, we demonstrated alterations in the expression profile of miRNA 100, 218 and let7c comparing localized and metastatic carcinomas. The characterization of expression profiles of their target proteins in PCa is crucial to understanding the processes involved in carcinogenesis, giving us the opportunity to discover new diagnostic or prognostic markers, and most importantly to find new targets for the development of innovative therapies. Objective: To analyze the expression of proteins controlled by miR-let7c (Ras, c- Myc and Bub1), miR-100 (Smarca5 and Retinoblastoma) and miR- 218 (Laminin 5 3) and proliferative activity (Ki-67) in prostate cancer with immunohistochemistry using tissue microarrays representing localized PCa, lymph node and bone metastases. To correlate the expression levels of miRNAs with their target proteins. To analyze the expression of miRNAs, proteins and proliferative activity with prognostic factors of prostate cancer and disease progression. Methods: The immunoexpression of Smarca5, Retinoblastoma, Laminin, Ras, c-Myc, Bub1 and Ki-67 was evaluated by IHC by tissue microarray technique featuring three stages of PCa, with 112 cases of localized PCa, 19 lymph node metastases and 28 bone metastases. The images obtained from IHC were submitted to analysis using the digital image software MacBiophotonics ImageJ from the National Institutes of Health, USA, where the intensity of luminescence was quantified densitometrically. We studied the expression profile of the miRNAs in the paraffin blocks of 61 patients out of the 112 patients with localized carcinoma, who underwent protein analysis by IHC. The processing of miRNA involved three steps: extraction of miRNA, generation of complementary DNA and amplification of the miRNA by quantitative real time PCR (qRT-PCR). To analyze the data we used a control endogenous RNU-43. The results were analyzed using the 2-CT formula. As control, we used the tissue from five patients with benign prostate hyperplasia (BPH) submitted to surgery. The relationship between the expression of miRNAs and their target proteins were analyzed as well as their expression with Gleason score, pathological stage and disease progression considered as PSA>0.4 ng/mL in a mean follow-up of 77.5 months. The statistical analysis was performed using SPSS 19.0 software, we used the Student t test, Mann-Whitney test, Kruskal- Wallis and chi-square. The value was considered statistically significant when p0.05. Results: There was a decrease in the expression of Ras (p=0.017) and Laminin (p<0.0001) according to PCa progression from localized to lymph node and bone metastases. There was an increase in the expression of Retinoblastoma (p=0.0361) and an increase in proliferative activity assessed by Ki-67 (p<0.0001). We also found a relationship between the positivity of c-Myc expression with pT3 staged tumors (p=0.070). All miRNAs showed overexpression in PCa samples. Laminin showed a higher expression together with higher expression of miR-218 (p=0.038). The other miRNAs did not show a relationship with protein expression by IHC. There was no correlation between the expression of miRNAs and protein expression by IHC with biochemical recurrence. Conclusions: Although our findings confirm the overexpression of miR-100, 218 and let7c in localized PCa, there was no correlation between their expression and the protein of their target using immunohistochemistry. We demonstrated that there was a change in immunostatining of Ras, Laminin 5 3, Retinoblastoma and Ki- 67 according to tumor progression. The increased expression of c- Myc per IHC showed a significant tendency to relate to tumor unconfined staged pT3

In dieser Arbeit wurde die Affinitätsreifung des murinen anti-c-myc-Peptid-Antikörpers 9E10 analysiert. Hierfür wurden Fab-Fragmente mit Keimbahnrückmutationen gentechnisch hergestellt und in ihrem Bindungsverhalten zum humanen c-myc-Peptid charakterisiert. Das von 9E10 erkannte Epitop besitzt die Aminosäuresequenz EQKLISEEDLLRKR mit den darin sehr selektiv erkannten Schlüsselpositionen LISEXXL.Der 3300-fache Affinitätsgewinn während der 9E10-Reifung kommt sowohl durch eine Zunahme der Assoziations- als auch durch eine Abnahme der Dissoziationsgeschwindigkeit des Komplexes zustande. Der Affinitätsgewinn resultiert weniger aus zusätzlichen Kontakten des Antikörpers zum Peptid, sondern vor allem aus der Beeinflussung der Konformation und/oder der Flexibilität der an der Bindung beteiligten CDRs. Die außergewöhnlich lange CDR-H3 liefert einen wesentlichen Beitrag zur Affinitätsreifung. Die variable leichte Domäne dient dabei mit der langen CDR-L1 und -L3 als eine Bindungsplattform für die flexible CDR-H3. Änderungen in der Spezifität von 9E10 sind vorrangig auf die Reifung der variablen schweren Domäne zurückzuführen. Dabei ist die selektive Erkennung der Schlüsselpositionen im Peptid im Anfangsstadium der Affinitätsreifung von 9E10 stark ausgeprägt. / In this work the affinity maturation of the murine anti c-myc-peptide antibody 9E10 was analysed. Therefore Fab fragments with reversed mutations directed towards germline genes were genetically produced and characterised for their binding to the human c-myc peptide. The epitope recognized by 9E10 consists of the amino acid sequence EQKLISEEDLLRKR of which the key positions LISEXXL are very selectively recognized. The maturation of 9E10 leads to a 3300-fold higher affinity, which is achieved by a faster association as well as by a slower dissociation of the complex. For the gain in affinity formation of additional contacts to the peptide is less important than conformational and/or flexibility changes of the CDRs which are involved in binding. The exceptionally long CDR-H3 contributes essentially to the affinity maturation. The variable light domain serves thereby with its long CDR-L1 and -L3 as a binding platform for the flexible CDR-H3. Changes in specificity of 9E10 are primarily due to maturation of the variable heavy domain. Selective recognition of the key positions in the peptide is already highly pronounced in the initial stage of affinity maturation of 9E10.

INTRODUÇÃO: O linfoma difuso de grandes células B, sem outras especificaçoes (LDGCB, SOE) é uma neoplasia agressiva caracterizada pela heterogeneidade morfológica, imunofenotípica e molecular, porém o atual tratamento padrão utilizando imunoquimioterapia (R-CHOP) não considera tal diversidade. Há percentual significativo de pacientes que são refratários à terapia de primeira linha e alguns que apresentam recidiva precoce ou tardia, os quais representam as vítimas desta doença. O estudo imuno-histoquímico (IHQ), que é um método simples e universalmente disponível, vem sendo utilizado para reconhecer a diversidade biológica do LDGCB, SOE, identificando biomarcadores e subgrupos distintos da doença, que poderiam predizer a resposta terapêutica ao tratamento padrão e apontar possíveis candidatos a novas estratégias terapêuticas. OBJETIVOS: Este estudo avalia o valor prognóstico de cinco algoritmos para classificação do LDGCB segundo a célula de origem (COO) e da expressão de três biomarcadores (BCL2, CD30 e MYC) tendo como endpoint a sobrevida global. MÉTODOS: Foi realizado estudo retrospectivo com setenta e nove pacientes com LDGCB,SOE de novo tratados com imunoquimioterapia padrão, estadiados e acompanhados protocolarmente. Os casos foram classificados como subgrupo célula B centrogerminativa símile (GCB) ou como subgrupo célula B não-centrogerminativa símile (NGCB), de acordo com três algoritmos IHQ (Hans, Choi, e Visco-Young) pareados com estudo do perfil de expressão gênica (PEG) e dois algoritmos IHQ não-PEG pareados (Muris e Nyman). Foi estimado o valor prognóstico destes algoritmos e também avaliado a concordância entre eles. O valor prognóstico da expressão do BCL2, CD30 e MYC utilizando IHQ também foi analisado. RESULTADOS: Os algoritmos IHQ PEG pareados revelaram maior concordância entre si, porém nenhum deles revelou força prognóstica. A expressão do CD30 mostrou tendência a melhor prognóstico, porém a expressão de BCL2 e MYC avaliados isoladamente não revelaram impacto prognóstico. Contudo, a coexpressão do BCL2 e MYC, denominado como fenótipo linfoma duplo-expressor (LDE), revelou-se importante marcador prognóstico desfavorável. Foram identificados três subgrupos de risco baseado no fenótipo LDE e o Índice Prognóstico Internacional (IPI). CONCLUSÃO: Em pacientes com LDGCB, SOE de novo tratados com esquema terapêutico padrão, a pesquisa da expressão do fenótipo LDE é mais relevante do ponto vista prognóstico que a classificação em subgrupo GCB ou NGCB. Além disso, a expressão do CD30 pode ser relevante tanto para identificar subgrupo com tendência a melhor prognóstico como para identificar possíveis candidatos a nova terapia alvo / BACKGROUND: Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is an aggressive neoplasm characterized by morphological, phenotypic and molecular heterogeneity, but the current standard therapy using immunochemotherapy (R-CHOP) does not consider such diversity. There is a significant percentage of patients who are refractory to first-line therapy and those with early or late recurrence, whose represent the victims of this disease. Immunohistochemistry (IHC), a simple and universally available method, has been used to recognize the biological diversity of DLBCL, NOS, to identify biomarkers and distinct subgroups of the disease, which would predict the therapeutic response to standard treatment and point possible candidates for novel therapeutic strategies. OBJECTIVES: The current study was conducted to evaluate the prognostic value from five algorithms for classification of DLBCL based on cell of origin (COO) and the expression of three biomarkers (BCL2, CD30 and MYC) with overall survival (OS) as an endpoint. METHODS: We retrospectively evaluated seventy nine patients with de novo DLBCL, NOS treated with R-CHOP-like immunochemotherapy. The cases were assigned as germinal center B-cell like (GCB) or non-GCB subgroup (NGCB) according to five different IHC algorithms, including three algorithms based on gene expressing profile study (GEP), proposed by Hans, Choi, and Visco-Young, and two non-GEP based algoritms proposed by Muris, and Nyman. We evaluated their prognostic relevance and the concordance between these algorithms. The prognostic power of BCL2, CD30 and MYC expression were also assessed by IHC. RESULTS: None of the profiles assessed by IHC algorithms was able to predict overall survival (OS). The positive expression of CD30 showed a trend toward a better outcome. Neither the positive expression of BCL2 nor the positive expression of MYC were associated with outcome. However, the double-expressor lymphoma phenotype (DEL), represented by the concurrent expression of MYC and BCL2, exhibited a negative prognostic impact. Three different risk subgroups were identified based on the DEL phenotype and the International Prognostic Index (IPI) score. CONCLUSIONS: These data suggest that the DEL, rather than the cell of origin classification based on IHC, is a better predictor of OS in patients with DLBCL treated with R-CHOP-like immunochemotherapy. Besides, the CD30 expression may be a useful prognostic marker and a possible therapeutic target

No description available.